
Agios Pharmaceuticals (($AGIO)) has held its Q3 earnings call. Read on for the main highlights of the call. Agios delivered a strongly positive third quarter, led by record revenue, rapid
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AGIO | Agios Pharma | 29.68 | -15.49 | -34.29% |
| Name | Price | % Change | |
|---|---|---|---|
| $29.68 | -34.29% |

Agios Pharmaceuticals (($AGIO)) has held its Q3 earnings call. Read on for the main highlights of the call. Agios delivered a strongly positive third quarter, led by record revenue, rapid

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $48 from $50 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source

H.C. Wainwright raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $62 from $55 and keeps a Buy rating on the shares. The firm sees the Aqvesme prescription trajectory

Truist lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $35 from $37 and keeps a Buy rating on the shares. Q&A on the earnings call largely centered on

Reports Q3 revenue $55.4M, consensus $51.6M. Agios expects that cash, cash equivalents and marketable securities, together with anticipated product revenue and interest income, will provide the financial independence to execute

H.C. Wainwright is surprised that the FDA extended the review period for Agios Pharmaceuticals (AGIO)’ mitapivat in sickle cell disease. The agency moved the drug’s action date by three months

Agios Pharmaceuticals (AGIO) announced that the FDA has extended the Prescription Drug User Fee Act, or PDUFA, goal date for the supplemental New Drug Application, or sNDA, for mitapivat, an

H.C. Wainwright analyst Douglas Tsao assumed coverage of Agios Pharmaceuticals (AGIO) with a Buy rating and $55 price target The firm believes the market is undervaluing the opportunity for mitapivat

Truist lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $37 from $39 and keeps a Buy rating on the shares as part of a broader research note previewing

BofA raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $50 from $46 and keeps a Buy rating on the shares. Despite falling off all-time highs over the past
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| buy | Reiterated | Nov 6, 2026 | ||||
| hold | Reiterated | Nov 5, 2026 | ||||
| hold | Reiterated | Oct 31, 2026 | ||||
| buy | Reiterated | Oct 28, 2026 | ||||
| buy | Reiterated | Aug 3, 2026 | ||||
| hold | Reiterated | Jul 21, 2026 | ||||
| buy | Reiterated | Jul 7, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 25, 2027TBA | $1.79B | $-1.11 | $63.53M | 0.02 | -4.69 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.